NeoGenomics Ownership
| NEO Stock | USD 18.25 0.08 0.44% |
Shares in Circulation | First Issued 1999-03-31 | Previous Quarter 126.4 M | Current Value 127 M | Avarage Shares Outstanding 56.1 M | Quarterly Volatility 41.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
NeoGenomics |
NeoGenomics Stock Ownership Analysis
About 100.0% of the company shares are owned by institutional investors. The book value of NeoGenomics was now reported as 7.09. The company has Price/Earnings (P/E) ratio of 272.37. NeoGenomics recorded a loss per share of 0.61. The entity had not issued any dividends in recent years. The firm had 1:100 split on the 16th of April 2003. NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company was founded in 2001 and is headquartered in Fort Myers, Florida. Neogenomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 2000 people. To find out more about NeoGenomics contact Christopher BSc at 239 768 0600 or learn more at https://www.neogenomics.com.Besides selling stocks to institutional investors, NeoGenomics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different NeoGenomics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align NeoGenomics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
NeoGenomics Quarterly Liabilities And Stockholders Equity |
|
NeoGenomics Insider Trades History
Only 1.2% of NeoGenomics are currently held by insiders. Unlike NeoGenomics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against NeoGenomics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of NeoGenomics' insider trades
NeoGenomics Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as NeoGenomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NeoGenomics backward and forwards among themselves. NeoGenomics' institutional investor refers to the entity that pools money to purchase NeoGenomics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 3.1 M | American Century Companies Inc | 2024-09-30 | 3 M | Goldman Sachs Group Inc | 2024-09-30 | 2.5 M | Franklin Resources Inc | 2024-09-30 | 2 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.9 M | Segall Bryant & Hamill | 2024-09-30 | 1.9 M | Fred Alger Management, Llc | 2024-09-30 | 1.8 M | Emerald Advisers, Llc | 2024-09-30 | 1.7 M | Bellevue Group Ag | 2024-09-30 | 1.6 M | Blackrock Inc | 2024-06-30 | 19.7 M | Vanguard Group Inc | 2024-09-30 | 14 M |
NeoGenomics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NeoGenomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on NeoGenomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NeoGenomics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NeoGenomics Outstanding Bonds
NeoGenomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NeoGenomics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NeoGenomics bonds can be classified according to their maturity, which is the date when NeoGenomics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| TNEMAK 3625 28 JUN 31 Corp BondUS64045DAC83 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US64049MAB63 Corp BondUS64049MAB63 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
NeoGenomics Corporate Filings
F4 | 10th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 4th of December 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Pair Trading with NeoGenomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoGenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoGenomics will appreciate offsetting losses from the drop in the long position's value.Moving together with NeoGenomics Stock
Moving against NeoGenomics Stock
| 0.8 | HCM | HUTCHMED DRC | PairCorr |
| 0.6 | VALN | Valneva SE ADR | PairCorr |
| 0.56 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.54 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.46 | LLY | Eli Lilly | PairCorr |
The ability to find closely correlated positions to NeoGenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoGenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoGenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoGenomics to buy it.
The correlation of NeoGenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoGenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoGenomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeoGenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.61) | Revenue Per Share 5.098 | Quarterly Revenue Growth 0.104 | Return On Assets (0.03) |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.